SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : QLT PhotoTherapeutics (QLTI)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Doug Lakin who wrote (25)8/13/1996 5:04:00 AM
From: Doug Meetmer   of 1321
 
Doug,

I know that QLT is testing BPD for age related macular degeneration,
but since it is a second generation product, it should still
be just as useful for treating a variety of cancers. The main
pitfall of photophrin is its long half life, which means people
need to stay out of the sun for up to four weeks, but from what
I know about BPD it is out of the body in a couple of days. If this
ios true thatn photophrin would appear to be a mere stepping stone
on the pathway to widespread approval of BPD for a variety of cancers
and inflammatory conditoons. My question of course is what will be the
subtle differences between a product such as BPD and Lu-Tex (pharmacyclics
product tht also has a short half life). There would probably be
some differences and it would be interesting to know how many of these
prodeucts the market will support.

Certainly interest in QLTIF will also boost PCYC and vice versa,
Let us hope for the best. This technology is fantastic and I
believe the best is yet to come.

Doug
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News